Yeda Research and Develpment & Co. Ltd

Varda Rotter

Moshe Oren

Perry Tal

Irun R Cohen

Johannes Herkel

Pedro Ruiz

Neta Erez-Alon

Ansgar W Lohse

Neta Erez

Avishai Mimran

Na'aman Kam

Roland Wolkowicz

Benjamin Geiger

Zvi Kam

Avi Ben-Shimon

Ami Navon

Shay Eizenberger

Irina Lavelin

An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.

Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53

The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.

Peptides capable of reactivating p53 mutants

A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.

Proteasome inhibitors and uses thereof

The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.

Peptide inhibitors for mediating stress responses

The invention relates to methods of inducing an anti-tumor immunity and/or inducing an immune responses to p53 in mammals. The methods comprise administering to a mammal an effective amount of at least one immunogen selected from the group consisting of: Preferably the peptide is 7 to 30 amino acid residues in length and contains a sequence of the CDR2 or CDR3 of the heavy chain, or of the CDR3 of the light chain of an anti-p53 mAb.

Immunogenic compositions for induction of anti-tumor immunity

The invention relates to the use of an immunogen selected from the group consisting of

Growing community of inventors

Rehovot, Israel

Varda Rotter